---
title: MitraClip and Tricuspid Valve Interventions - Minimally Invasive Valve Treatment
description: MitraClip and tricuspid valve interventions in Istanbul. Assoc. Prof.
  Dr. Habib Çil treats mitral and tricuspid regurgitation. Minimally invasive catheter
  method. Avrasya Hospital.
date: 2024-12-05
lastmod: 2024-12-05
draft: false
author: Assoc. Prof. Dr. Habib ÇİL
categories:
- Interventional Cardiology
tags:
- Heart Valve Diseases
translationKey: mitraclip-tricuspid-interventions
showTableOfContents: true
faq:
- question: Is MitraClip surgery or a catheter procedure?
  answer: MitraClip is not open-heart surgery. It is a minimally invasive procedure
    performed via catheter through the groin. It is done under general anesthesia
    but does not require opening the chest or using a heart-lung machine. Therefore,
    recovery time is much shorter and complication risk is lower.
- question: How long does MitraClip procedure take and how long is hospital stay?
  answer: MitraClip procedure typically takes 2-4 hours. Hospital stay is 1-3 days
    for uncomplicated cases. Considering that open-heart surgery requires 7-10 days
    of hospitalization, this is a significant advantage. Most patients can walk 24-48
    hours after the procedure.
- question: Is tricuspid valve regurgitation dangerous?
  answer: Severe tricuspid regurgitation can lead to right heart failure and significantly
    reduce quality of life. It causes symptoms such as leg swelling, fluid accumulation
    in the abdomen, liver enlargement, and fatigue. If left untreated, hospitalizations
    increase and survival decreases. Early diagnosis and appropriate treatment can
    prevent these complications.
- question: Which patients are suitable for MitraClip?
  answer: MitraClip is performed on patients with severe mitral regurgitation who
    are at high risk for open-heart surgery. It is an ideal option for patients at
    high surgical risk due to advanced age, low heart function, comorbidities, or
    previous heart surgeries. Additionally, valve anatomy must be suitable.
- question: When can I return to normal life after MitraClip?
  answer: Most patients can return to daily activities within 1-2 weeks. Light exercise
    can begin after 1 week, heavy lifting and intense exercise after 4-6 weeks. Since
    this period is 2-3 months for open-heart surgery, MitraClip provides a significant
    advantage. However, each patient's recovery process is different.
- question: What methods are used for tricuspid valve interventions?
  answer: Catheter methods such as TriClip, PASCAL, and Cardioband have been developed
    for tricuspid regurgitation. These methods are applied minimally invasively similar
    to MitraClip. Although not yet as widespread as MitraClip, they show promising
    results especially in patients at high surgical risk. Method selection is based
    on patient anatomy and clinical condition.
- question: What is the success rate of MitraClip procedure?
  answer: The technical success rate of MitraClip procedure is 80-90%. In most patients,
    mitral regurgitation is significantly reduced and symptoms improve. Quality of
    life increases, hospitalizations decrease, and survival advantage is provided
    in some patient groups. Success rate is even higher in experienced centers and
    with appropriate patient selection.
- question: What are the risks of MitraClip procedure?
  answer: Since MitraClip is a minimally invasive procedure, complication risk is
    low. Possible risks include clip detachment (2-3%), mitral stenosis formation,
    vascular complications, bleeding, and infection. Serious complications are rare
    and risk is even lower in experienced centers. Risks are minimized with detailed
    pre-procedure evaluation.
- question: Do I need to continue medication after MitraClip?
  answer: Yes, heart failure medications should be continued after MitraClip. Blood
    thinners are used for the first 3-6 months after the procedure. Additionally,
    heart failure medications such as ACE inhibitors, beta blockers, and diuretics
    are optimized. Medication therapy and MitraClip together provide the best results.
    Medication changes should be made under doctor supervision.
- question: Can tricuspid valve regurgitation resolve on its own?
  answer: Functional (secondary) tricuspid regurgitation may decrease if the underlying
    cause is treated. For example, if mitral valve disease is corrected or heart failure
    treatment is optimized, tricuspid regurgitation may also improve. However, severe
    and long-standing regurgitation is usually permanent and requires treatment. Early
    intervention provides better results.
---

{{< alert type="info" >}}
This content has been prepared for informational purposes to protect public health, in compliance with the regulations of the Ministry of Health of the Republic of Turkey and medical ethical rules. It does not provide any diagnosis, treatment guarantees, or specific medical advice. Please consult a qualified healthcare provider for the most accurate information.
{{< /alert >}}


{{< lead >}}
Heart valve diseases, especially mitral and tricuspid regurgitation, are conditions that seriously affect quality of life. While traditional open-heart surgery carries high risk for many patients, minimally invasive methods such as MitraClip and tricuspid valve interventions offer promising alternatives. In this comprehensive guide, I will discuss non-surgical valve treatment methods, indications, procedure process, and expected outcomes in detail.
{{< /lead >}}

## What is Heart Valve Regurgitation?

Heart valves are structures that ensure one-way blood flow between heart chambers and between the heart and major vessels. Valve regurgitation means the valve does not close completely, causing blood to leak backward. This creates extra load on the heart and can lead to heart failure over time.

### Mitral Valve Regurgitation

The mitral valve is located between the left atrium and left ventricle. Mitral regurgitation is one of the most common valve diseases and occurs in two main types:

**Primary (Organic) Mitral Regurgitation:**

-   Degeneration of valve leaflets
-   Mitral valve prolapse
-   Chordae tendineae rupture
-   Rheumatic valve disease
-   Infective endocarditis

**Secondary (Functional) Mitral Regurgitation:**

-   Left ventricular dilatation due to heart failure
-   Post-ischemic heart disease
-   Dilated cardiomyopathy
-   Valve structure normal but geometry distorted

### Tricuspid Valve Regurgitation

The tricuspid valve is the valve between the right atrium and right ventricle. Tricuspid regurgitation is usually secondary and develops due to other heart diseases:

**Secondary Tricuspid Regurgitation:**

-   Due to left heart valve diseases
-   Pulmonary hypertension
-   Right ventricular dilatation
-   Atrial fibrillation

**Primary Tricuspid Regurgitation:**

-   Rheumatic disease
-   Carcinoid syndrome
-   Trauma
-   Due to pacemaker leads
-   Congenital anomalies

## Symptoms of Valve Regurgitation

Symptoms of valve regurgitation vary depending on disease severity and which valve is affected.

### Mitral Regurgitation Symptoms

-   **Shortness of breath:** Especially with exertion and when lying down
-   **Fatigue:** Unusual weakness and energy loss
-   **Palpitations:** Irregular or rapid heartbeat
-   **Edema:** Leg swelling
-   **Orthopnea:** Shortness of breath when lying down
-   **Paroxysmal nocturnal dyspnea:** Waking up at night with shortness of breath

### Tricuspid Regurgitation Symptoms

-   **Peripheral edema:** Prominent swelling in legs and ankles
-   **Ascites:** Fluid accumulation in abdomen
-   **Hepatomegaly:** Liver enlargement
-   **Jugular vein distension:** Fullness in neck veins
-   **Right upper quadrant pain:** Due to liver congestion
-   **Fatigue and weakness:** Due to low cardiac output

{{< alert "danger" >}}
**Emergency Warning:** Call 911 immediately if you experience sudden severe shortness of breath, chest pain, fainting, or pink frothy sputum! These symptoms may indicate acute heart failure.
{{< /alert >}}

## What is MitraClip?

MitraClip is a revolutionary device that enables catheter-based treatment of mitral valve regurgitation. First used in 2003, this method has now been applied to tens of thousands of patients worldwide.

### Working Principle of MitraClip

MitraClip improves valve closure by holding the anterior and posterior leaflets of the mitral valve together. This technique is the catheter version of the surgical technique developed by Alfieri in the 1960s.

**MitraClip System Components:**

-   **Clip device:** Made of cobalt-chromium alloy, 4 mm wide
-   **Guide catheter:** For access to left atrium
-   **Steerable catheter:** For clip positioning
-   **Delivery system:** Clip placement mechanism

### Advantages of MitraClip

**Advantages Over Open-Heart Surgery:**

-   No chest opening, no sternotomy
-   No heart-lung machine required
-   Short hospital stay (1-3 days vs 7-10 days)
-   Rapid recovery and return to normal
-   Low complication risk
-   Can be safely performed in high-risk patients
-   Can be repeated if necessary
-   Does not eliminate future surgical option

## MitraClip Indications

MitraClip is not performed on all mitral regurgitation patients. Patient selection is very important and should be evaluated by a multidisciplinary heart team.

### Primary Mitral Regurgitation

**Suitable Patients:**

-   Severe symptomatic mitral regurgitation (3+ or 4+)
-   High surgical risk (STS score ≥8% or)
-   High-risk assessment by heart team
-   Suitable valve anatomy

**Anatomic Criteria:**

-   Adequate leaflet length (≥10 mm)
-   Coaptation depth <11 mm
-   Flail width <15 mm
-   Minimal calcification

### Secondary Mitral Regurgitation

**Suitable Patients:**

-   Functional mitral regurgitation (2+ or greater)
-   Heart failure symptoms (NYHA II-IV)
-   Symptoms despite optimal medical therapy
-   Left ventricular ejection fraction 20-50%
-   Left ventricular end-systolic diameter <70 mm

### Contraindications

**Absolute Contraindications:**

-   Rheumatic mitral stenosis
-   Active endocarditis
-   Intracardiac thrombus
-   Severe mitral annular calcification

**Relative Contraindications:**

-   Very advanced heart failure (NYHA IV, inotropic support)
-   Severe right heart failure
-   Severe pulmonary hypertension
-   Unsuitable anatomic features

## Pre-MitraClip Evaluation

A comprehensive evaluation is performed before MitraClip procedure. This evaluation determines whether the patient is suitable for the procedure and meets anatomic criteria.

### Imaging Methods

**Transthoracic Echocardiography (TTE):**

-   Severity of mitral regurgitation
-   Left ventricular function and dimensions
-   Pulmonary artery pressure
-   Concomitant valve diseases

**Transesophageal Echocardiography (TEE):**

-   Detailed valve anatomy
-   3D imaging for leaflet assessment
-   Coaptation point and depth
-   Flail segment localization
-   Left atrial appendage thrombus screening

**Cardiac Computed Tomography (CT):**

-   Additional anatomic information when needed
-   Vascular access assessment
-   Coronary artery anatomy

### Additional Evaluations

**Coronary Angiography:**

-   Screening for concomitant coronary artery disease
-   Revascularization planning if needed

**Right Heart Catheterization:**

-   Pulmonary artery pressures
-   Cardiac output measurement
-   Pulmonary vascular resistance

**Laboratory Tests:**

-   Complete blood count
-   Kidney and liver functions
-   Coagulation parameters
-   BNP/NT-proBNP levels

**General Condition Assessment:**

-   Functional capacity (6-minute walk test)
-   Frailty assessment
-   Comorbidities
-   Life expectancy

## How is MitraClip Procedure Performed?

MitraClip procedure is performed by an experienced interventional cardiology team in a hybrid operating room or catheterization laboratory.

### Pre-Procedure Preparation

-   **Fasting:** 6-8 hours before procedure
-   **Medications:** Blood thinners stopped with bridge therapy
-   **Anesthesia assessment:** Suitability for general anesthesia
-   **Consent:** Detailed information and written consent

### Procedure Steps

**1. Anesthesia and Monitoring**

-   General anesthesia administered
-   TEE probe placed
-   Hemodynamic monitoring

**2. Vascular Access**

-   Right femoral vein puncture
-   Guide wire advancement
-   Sheath placement

**3. Transseptal Puncture**

-   Passage from right atrium to left atrium
-   Atrial septum puncture with needle
-   Optimal puncture site selection (superior-posterior)

**4. Guide Catheter Placement**

-   24F guide catheter advanced to left atrium
-   Steerable catheter passed through

**5. MitraClip System Preparation**

-   Clip device advanced through guide catheter
-   Positioned over mitral valve
-   Optimal position achieved with TEE guidance

**6. Leaflet Capture**

-   Clip opened and placed between leaflets
-   Anterior leaflet captured
-   Posterior leaflet captured
-   Both leaflets confirmed in clip

**7. Result Evaluation**

-   Mitral regurgitation degree checked with TEE
-   Mitral stenosis formation assessed
-   Transmitral gradient measured

**8. Clip Release or Repositioning**

-   Clip released if result satisfactory
-   Clip repositioned if inadequate
-   Additional clip placed if needed (average 1-2 clips)

**9. Procedure Completion**

-   All catheters removed
-   Femoral vein hemostasis achieved
-   Patient taken to recovery room

### Procedure Duration and Hospital Stay

-   **Procedure duration:** 2-4 hours (varies with experience)
-   **Intensive care:** 24-hour monitoring
-   **Hospital stay:** 1-3 days (uncomplicated cases)
-   **Discharge criteria:** Stable hemodynamics, no complications, successful mobilization

## Tricuspid Valve Interventions

Tricuspid regurgitation treatment has been a neglected area for many years. However, catheter methods developed in recent years offer hope to patients at high surgical risk.

### Tricuspid Regurgitation Treatment Options

**Medical Treatment:**

-   Diuretics (for fluid removal)
-   Sodium restriction
-   Treatment of underlying disease
-   Heart failure medication optimization

**Surgical Treatment:**

-   Tricuspid valve repair (annuloplasty)
-   Tricuspid valve replacement
-   Usually performed with left heart surgery
-   Isolated tricuspid surgery is high risk

### Transcatheter Tricuspid Interventions

Various catheter methods have been developed for tricuspid regurgitation:

**TriClip (Abbott):**

-   Tricuspid valve version of MitraClip
-   Edge-to-edge repair principle
-   CE approved, FDA approval process
-   Early results promising

**PASCAL (Edwards Lifesciences):**

-   Wide capture area
-   Spacer technology
-   Can be used for both mitral and tricuspid

**Cardioband (Edwards Lifesciences):**

-   Annulus reconstruction
-   Ring-like implant
-   Reduces annulus size

**Other Developing Technologies:**

-   Tricinch
-   Trialign
-   Forma
-   Valve replacement systems (EVOQUE, Intrepid)

### Tricuspid Intervention Indications

**Suitable Patients:**

-   Severe symptomatic tricuspid regurgitation
-   Symptoms despite medical therapy
-   High surgical risk
-   Suitable anatomic features
-   Life expectancy >1 year

**Evaluation:**

-   Detailed echocardiography
-   Right ventricular function
-   Pulmonary artery pressures
-   Liver functions
-   General condition assessment

## MitraClip and Tricuspid Intervention Outcomes

### MitraClip Clinical Outcomes

**COAPT Study (Secondary MR):**

-   47% reduction in hospitalizations
-   38% reduction in mortality (2 years)
-   Significant improvement in quality of life
-   Increase in functional capacity

**EVEREST II Study (Primary MR):**

-   80-90% technical success
-   Symptom control as effective as surgery
-   Lower complication risk
-   Shorter hospital stay

**Real-World Data:**

-   Over 100,000 patients treated
-   95%+ success in experienced centers
-   Long-term durability proven
-   Sustained quality of life improvement

### Tricuspid Intervention Early Results

**TriClip Studies:**

-   70-80% technical success
-   ≥1 grade reduction in tricuspid regurgitation
-   Symptom improvement
-   Increase in 6-minute walk distance
-   Quality of life improvement

**Long-Term Data:**

-   Limited long-term data yet
-   Early results promising
-   Randomized trials ongoing

## Complications and Risks

### MitraClip Complications

**Major Complications (<5%):**

-   Clip detachment or embolization
-   Severe mitral stenosis formation
-   Cardiac tamponade
-   Stroke
-   Vascular complications
-   Death (<1%)

**Minor Complications:**

-   Atrial septal defect (usually small and clinically insignificant)
-   Transient arrhythmia
-   Bleeding
-   Infection
-   Kidney function impairment

### Tricuspid Intervention Complications

-   Clip/device detachment
-   Tricuspid stenosis
-   Right ventricular injury
-   Pericardial effusion
-   Vascular complications

{{< alert "warning" >}}
**Important:** Complication risk is minimal in experienced centers and with appropriate patient selection. Pre-procedure detailed evaluation and multidisciplinary approach reduce risks.
{{< /alert >}}

## Post-Procedure Care and Follow-up

### Hospital Period

**First 24 Hours:**

-   Intensive care monitoring
-   Hemodynamic stability check
-   Echocardiography control
-   Early mobilization

**Before Discharge:**

-   Control echocardiography
-   Medication adjustment
-   Patient education
-   Follow-up planning

### After Discharge

**Medication Therapy:**

-   Anticoagulation: First 3-6 months (aspirin + clopidogrel)
-   Heart failure medication optimization
-   ACE inhibitors/ARB/ARNI
-   Beta blockers
-   Mineralocorticoid receptor antagonists
-   SGLT2 inhibitors
-   Diuretics (if needed)

**Lifestyle Recommendations:**

-   Salt restriction (2-3 grams/day)
-   Fluid restriction (if needed)
-   Regular weight monitoring
-   Gradual activity increase
-   Smoking and alcohol cessation

**Follow-up Program:**

-   1st month: Clinical evaluation and echocardiography
-   3rd month: Control examination
-   6th month: Detailed evaluation
-   Thereafter: Follow-up every 6-12 months

### Physical Activity and Exercise

**First Week:**

-   Light walking
-   Daily activities
-   Avoid heavy lifting

**2-4 Weeks:**

-   Gradual exercise increase
-   Moderate walking
-   Stair climbing

**After 4-6 Weeks:**

-   Return to normal activities
-   Cardiac rehabilitation program
-   Regular exercise routine

## Cardiac Rehabilitation

Participation in cardiac rehabilitation program is recommended after MitraClip and tricuspid intervention:

**Rehabilitation Components:**

-   Supervised exercise program
-   Nutritional counseling
-   Psychological support
-   Risk factor management
-   Patient education

**Benefits:**

-   Increased functional capacity
-   Quality of life improvement
-   Reduced hospitalizations
-   Reduced mortality
-   Increased confidence

## Frequently Asked Questions (FAQ)

{{< faq-list >}}

## When Should You See a Doctor?

Consult a cardiologist without delay in the following situations:

-   New or worsening shortness of breath
-   Increased swelling in legs, ankles, or abdomen
-   Unusual fatigue and weakness
-   Palpitations or irregular heartbeat
-   Chest pain or pressure
-   Fainting or feeling faint
-   Waking up at night with shortness of breath

If you have been diagnosed with mitral or tricuspid valve disease, regular cardiology follow-up is important. Early evaluation and timely intervention provide the best results.

---

## Appointment and Contact

If you would like to schedule an appointment for MitraClip or tricuspid valve intervention evaluation:

{{< button href="https://wa.me/905339454639" target="_blank" >}}
Book Appointment via WhatsApp
{{< /button >}}

📍 **Avrasya Hospital** - Beştelsiz Mah. 101. Sokak No:107, Zeytinburnu, Istanbul

📞 **Phone:** +90 212 665 50 50 (Ext: 4012)

---

## Related Valve Treatments

-   [TAVI - Transcatheter Aortic Valve Replacement](/services/tavi/)
-   [Mitral Valve Disease](/services/mitral-valve/)
-   [Tricuspid Valve Disease](/services/tricuspid-valve/)
-   [Balloon Valvuloplasty](/services/balloon-valvuloplasty/)
-   [Echocardiography](/services/echocardiography/)
-   [Heart Failure Treatment](/services/heart-failure/)
